6533b832fe1ef96bd129ad15

RESEARCH PRODUCT

Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials.

Behzad BaradaranSaeed KhaliliMiguel De La GuardiaAhad MokhtarzadehJafar MosaferTayebeh RezaeiSarah Rezaei

subject

Pharmaceutical ScienceHIV Infections02 engineering and technologyVirusDNA vaccination03 medical and health sciencesImmune systemAcquired immunodeficiency syndrome (AIDS)AntigenAdjuvants ImmunologicmedicineVaccines DNAAnimalsHumansVector (molecular biology)030304 developmental biologyAIDS Vaccines0303 health sciencesClinical Trials as TopicImmunity Cellularbusiness.industryVaccination021001 nanoscience & nanotechnologymedicine.diseaseImmunity HumoralVaccinationClinical trialImmunology0210 nano-technologybusiness

description

According to WHO (World Health Organization) reports, more than 770,000 people died from HIV and almost 1.7 million people becoming newly infected in the worldwide in 2018. Therefore, many attempts should be done to produce a forceful vaccine to control the AIDS. DNA-based vaccines have been investigated for HIV vaccination by researches during the recent 20 years. The DNA vaccines are novel approach for induction of both type of immune responses (cellular and humoral) in the host cells and have many advantages including high stability, fast and easy of fabrication and absence of severe side effects when compared with other vaccination methods. Recent studies have been focused on vaccine design, immune responses and on the use of adjuvants as a promising strategy for increased level of responses, delivery approaches by viral and non-viral methods and vector design for different antigens of HIV virus. In this review, we outlined the aforementioned advances on HIV DNA vaccines. Then we described the future trends in clinical trials as a strong strategy even in healthy volunteers and the potential developments in control and prevention of HIV.

10.1016/j.jconrel.2019.10.045https://pubmed.ncbi.nlm.nih.gov/31669566